Table 1. Clinical correlation of TRIM14 expression in NSCLC patients.
| Cohort | Univariate Survival Analysis |
TRIM14 (probe set: 203147_s_at) |
||||
|---|---|---|---|---|---|---|
| Tumor Type | Platform | No. patients | Hazard Ratio | 95% CI | P-value | |
| JBR.10 | NSCLC | U133A | 62 | 0.22 | 0.09–0.56 | 0.002 |
| DCC | ADC | U133A | 311 | 0.61 | 0.40–0.94 | 0.026 |
| UHN | NSCLC | U133A plus2.0 | 181 | 1.48 | 0.98–2.22 | 0.063 |
| Michigan | SQC | U133A | 129 | 1.17 | 0.48–2.83 | 0.733 |
| Multivariate Survival Analysis | TRIM14 (probe set: 203147_s_at) | |||||
| JBR.10 | NSCLC | U133A | 62 | 0.23 | 0.08–0.66 | 0.006 |
| DCC | ADC | U133A | 311 | 0.61 | 0.40–0.95 | 0.030 |
| UHN | NSCLC | U133A plus2.0 | 181 | 1.41 | 0.93–2.14 | 0.111 |
| Michigan | SQC | U133A | 129 | 1.19 | 0.49–2.89 | 0.706 |
Abbreviations: DCC, Director’s Challenge Consortium adenocarcinoma; NSCLC, non-small cell lung cancer; UHN, University Health Network; U133A, Affymetrix U133A chip; ADC, adenocarcinoma; SQC, squamous cell carcinoma.
*Hazard ratio compares the overall survival of the high-risk (poor prognosis) patient group to that of the low-risk (good prognosis) group.